Clinical Trial

A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck

Study acronym: NIVOPOSTOP
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the efficacy of nivolumab + cisplatin-RT relative to standard of care (SOC) cisplatin-RT alone, using the disease-free survival (DFS by investigator imaging assessment) as primary endpoint )
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2018-06-21; most recent amendment 2025-05-06.
Status change: Recruiting → Active, Not Recruiting 2024-07-03
Status change: Not Yet Recruiting → Recruiting 2018-10-23
Trial Details
NCT Number NCT03576417
Lead Sponsor Groupe Oncologie Radiotherapie Tete et Cou
Collaborators: For Drug Consulting, Eurofins
Conditions Squamous Cell Carcinoma of Head and Neck
Enrollment 680 participants
Start Date 2018-10-10
Primary Completion 2027-08 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2025-05-07